Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00694655 · ClinicalTrials.gov registry record · Phase 4
Human Immune Responses to Yellow Fever Vaccination
A Phase 4 study, sponsored by Emory University.
- Completed
- Registry status
- Phase 4
- Development phase
- 239
- Enrollment target
NCT00694655: Completed Phase 4 study, sponsored by Emory University.
NCT00694655 is a Phase 4 study that has completed, run by Emory University. The registered enrollment target is 239 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (54% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00694655, a Phase 4 study, has completed, sponsored by Emory University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 239 participants
- Enrollment target
Study Summary
The goal of this study is to use the live attenuated Yellow Fever Vaccine (YFV) as a safe and effective model for viral infection to understand human immune response to viral antigens. Study participants will receive the yellow fever vaccine and participation in the study may be as short as one month or as long as one year, depending on immune responses.
Primary Outcome
The characterization of Yellow Fever Vaccine specific adaptive immune response will be examined as the magnitude of YFV-specific T cell responses. The schedule of follow up visits depends on if participants test positive for human leukocyte antigen (HLA) A202 and the different immune system responses that the study team is examining at the time when each participant enrolls.
Interventions
- PROCEDURE Leukapheresis
- BIOLOGICAL Yellow Fever Vaccine
- PROCEDURE Fine-needle aspiration (FNA)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 239 participants |
| Start Date | 2008-05 |
| Est. Completion | 2024-08-29 |
| Phase | Phase 4 |
What the finished NCT00694655 record still lists
NCT00694655 is an interventional study that assigns participants to a tested intervention. The registered 239 participants enrollment target is mid-sized for trials with a published cap, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (54% lower).
The record links to 0 conditions, and to 3 interventions - of which Leukapheresis is the first listed.
NCT00694655 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00694655 about?
NCT00694655 is a clinical study titled "Human Immune Responses to Yellow Fever Vaccination". The goal of this study is to use the live attenuated Yellow Fever Vaccine (YFV) as a safe and effective model for viral infection to understand human immune response to viral antigens. Study participants will receive the yellow fever vaccine and participation in the study may be as short as one mont...
What is the current status of trial NCT00694655?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 239 participants. The study started on 2008-05. Estimated completion is 2024-08-29.
What interventions are being tested in trial NCT00694655?
The interventions under investigation include: Leukapheresis (PROCEDURE), Yellow Fever Vaccine (BIOLOGICAL), Fine-needle aspiration (FNA) (PROCEDURE).
Who is sponsoring clinical trial NCT00694655?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00694655's enrollment target sits among peer trials
239 366th of 2000 higher than 1,634 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02855554 · 240 participants · NA
Quantitative Cardiac Parametric Mapping
- NCT03230565 · 240 participants · Phase 4
Continuous Infusions vs Scheduled Bolus Infusions
- NCT03399929 · 240 participants
Traumatic Brain Injury and Stroke Long Term Outcome
- NCT03583710 · 240 participants · Phase 3
Mitotane With or Without Cisplatin and Etoposide After Surgery in Treating Patients With Stage I-III Adrenocortical Cancer With High Risk of Recurrence
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia